Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inmune Bio, Inc.INMB · Entity 7094 | Director | July 02, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inmune Bio, Inc.
Report date July 02, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,404 |
Reported balance
After 2026-07-02 transaction · row 1
1 source rowRow 1 · 2026-07-02 · Exercise / conversion · Acquired 14,801 · Balance 86,404 F1: Represents 14,801 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person. The Reporting Person and other holders of common stock purchase warrants previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the "April 2024 Warrants"), entered into a warrant inducement offer letter agreement with the Issuer (the "Inducement Letter"). Pursuant to the Inducement Letter, the Reporting Person agreed to exercise, for cash, 14,801 April 2024 Warrants, representing 50% of the April 2024 Warrants held by it, and agreed to purchase 14,801 shares of common stock at a reduced exercise price of $1.40 in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised, from June 30, 2026, to December 31, 2027. |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2027-12-31 | Direct | 14,802 |
Reported balance
After 2026-07-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-02 · Other · Disposed 14,801 · Balance 14,802 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 14,801 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person. The Reporting Person and other holders of common stock purchase warrants previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the "April 2024 Warrants"), entered into a warrant inducement offer letter agreement with the Issuer (the "Inducement Letter"). Pursuant to the Inducement Letter, the Reporting Person agreed to exercise, for cash, 14,801 April 2024 Warrants, representing 50% of the April 2024 Warrants held by it, and agreed to purchase 14,801 shares of common stock at a reduced exercise price of $1.40 in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised, from June 30, 2026, to December 31, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2026 Filed Jul 7, 2026 11:01 UTC | Inmune Bio, Inc. INMB · Entity 7094 | OtherCommon Stock Purchase Warrant · Derivative | 14,801 | $0.13 Strike: $1.40 | $1,850.13 |
DisclosureSEC source: 0001213900-26-075738 · ownership.xml · derivative · entry 2 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,802 Underlying: Common Stock · 14,801 shares Expires 2027-12-31 Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 11:01 UTC | Inmune Bio, Inc. INMB · Entity 7094 | Exercise / conversionCommon Stock | 14,801 | $1.40 | $20,721.40 |
DisclosureSEC source: 0001213900-26-075738 · ownership.xml · nonDerivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents 14,801 shares of Common Stock acquired upon exercise of common stock purchase warrants held by the Reporting Person. The Reporting Person and other holders of common stock purchase warrants previously issued by the Issuer in its April 2024 offerings on April 24, 2024 and April 29, 2024, as such warrants were amended on December 22, 2025 (the "April 2024 Warrants"), entered into a warrant inducement offer letter agreement with the Issuer (the "Inducement Letter"). Pursuant to the Inducement Letter, the Reporting Person agreed to exercise, for cash, 14,801 April 2024 Warrants, representing 50% of the April 2024 Warrants held by it, and agreed to purchase 14,801 shares of common stock at a reduced exercise price of $1.40 in exchange for the Issuer's agreement to extend the maturity date of the April 2024 Warrants, as it relates to the remaining 50% of the April 2024 Warrants that were not exercised, from June 30, 2026, to December 31, 2027. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:40 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001213900-25-117303 · ownership.xml · derivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-11-23 F1 · derivative.exercise_date: Granted pursuant to the Issuer's Second Amended and Restated 2021 Stock Incentive Plan. The option will become vested and exercisable pro rata on a monthly basis over three (3) years (1/36 per month) until the option is 100% vested, which shall occur on the three-year anniversary of the date of grant. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantStock Option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 16 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-05-13 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | Disposition to issuerStock Option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $9.92 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 15 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2034-05-13 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantStock Option (right to buy) · Derivative | 32,500 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 14 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2034-12-04 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | Disposition to issuerStock Option (right to buy) · Derivative | 32,500 | Not disclosed Strike: $5.05 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 13 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,500 shares Expires 2034-12-04 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 12 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-02-15 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | Disposition to issuerStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $9.74 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 11 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2033-02-15 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 10 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-03-20 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | Disposition to issuerStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $7.92 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 9 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2032-03-20 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantStock Option (right to buy) · Derivative | 19,025 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 8 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,025 Underlying: Common Stock · 19,025 shares Expires 2031-06-21 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | Disposition to issuerStock Option (right to buy) · Derivative | 19,025 | Not disclosed Strike: $17.49 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 7 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,025 shares Expires 2031-06-21 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantStock Option (right to buy) · Derivative | 15,975 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 6 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,975 Underlying: Common Stock · 15,975 shares Expires 2031-01-18 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | Disposition to issuerStock Option (right to buy) · Derivative | 15,975 | Not disclosed Strike: $24.82 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 5 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,975 shares Expires 2031-01-18 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantStock Option (right to buy) · Derivative | 108,000 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 4 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,000 Underlying: Common Stock · 108,000 shares Expires 2029-11-24 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | Disposition to issuerStock Option (right to buy) · Derivative | 108,000 | Not disclosed Strike: $3.91 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 3 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,000 shares Expires 2029-11-24 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantStock Option (right to buy) · Derivative | 108,000 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 2 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,000 Underlying: Common Stock · 108,000 shares Expires 2028-04-01 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| November 18, 2025 Filed Nov 18, 2025 22:27 UTC | Inmune Bio, Inc. INMB · Entity 7094 | Disposition to issuerStock Option (right to buy) · Derivative | 108,000 | Not disclosed Strike: $7.80 | Not disclosed |
DisclosureSEC source: 0001213900-25-112232 · ownership.xml · derivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,000 shares Expires 2028-04-01 F1 · kind: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 21:00 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption (right to buy) · Derivative | 32,500 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0001213900-24-106915 · ownership.xml · derivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2034-12-04 F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. The option will become 100% vested and exercisable on December 5, 2026, the two-year anniversary of the grant date. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 12:00 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 5,000 | $7.27 | $36,350.00 |
DisclosureSEC source: 0001213900-24-055920 · ownership.xml · nonDerivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 71,603 F1 · ownership.nature: The Reporting Person's shares are held by Fossick Capital LP ("Fossick"), a limited partnership. The Reporting Person holds all voting and dispositive control over the Issuer's shares of common stock held by Fossick. Read SEC document |
| May 14, 2024 Filed May 16, 2024 20:08 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption (right to buy) · Derivative | 12,500 | $0.00 Strike: $9.92 | $0.00 |
DisclosureSEC source: 0001213900-24-044306 · ownership.xml · derivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-05-13 F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. The Option will become vested and exercisable 1/12th every month until the Option is 100% vested which shall occur on the one-year anniversary of the grant date. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 21:53 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantCommon Stock Warrants (right to buy) · Derivative | 29,603 | $0.13 Strike: $9.15 | $3,700.38 |
DisclosureSEC source: 0001213900-24-035471 · ownership.xml · derivative · entry 2 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,603 Underlying: Common Stock · 29,603 shares Expires not disclosed F1 · derivative.expiration_date: The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $249,997.34 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 21:53 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantCommon Stock | 29,603 | $8.32 | $246,296.96 |
DisclosureSEC source: 0001213900-24-035471 · ownership.xml · nonDerivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,603 F1 · shares: The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $249,997.34 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant. Read SEC document |
| April 19, 2024 Filed Apr 24, 2024 18:07 UTC Amendment | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 29,603 | $0.13 Strike: $9.15 | $3,700.38 |
DisclosureSEC source: 0001213900-24-035720 · ownership.xml · derivative · entry 2 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,603 Underlying: Common Stock · 29,603 shares Expires not disclosed F1 · derivative.expiration_date: The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $249,997.34 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant. Read SEC document |
| April 19, 2024 Filed Apr 24, 2024 18:07 UTC Amendment | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 29,603 | $8.32 | $246,296.96 |
DisclosureSEC source: 0001213900-24-035720 · ownership.xml · nonDerivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,603 F1 · shares: The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $249,997.34 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant. Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 16:31 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 7,000 | $6.95 | $48,650.00 |
DisclosureSEC source: 0001213900-23-085758 · ownership.xml · nonDerivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 37,000 F1 · ownership.nature: The Reporting Person's shares are held by Fossick Capital LP ("Fossick"), a limited partnership. The Reporting Person holds all voting and dispositive control over the Issuer's shares of common stock held by Fossick. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 21:08 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption (right to buy) · Derivative | 35,000 | $0.00 Strike: $9.74 | $0.00 |
DisclosureSEC source: 0001213900-23-013284 · ownership.xml · derivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:29 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption (right to buy) · Derivative | 35,000 | $0.00 Strike: $7.92 | $0.00 |
DisclosureSEC source: 0001213900-22-014500 · ownership.xml · derivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-03-20 F1 · derivative.exercise_date: Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date. Read SEC document |
| November 17, 2021 Filed Nov 17, 2021 23:10 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 2,500 | $13.55 | $33,875.00 |
DisclosureSEC source: 0001213900-21-060386 · ownership.xml · nonDerivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 30,000 F1 · ownership.nature: The Reporting Person's shares are held by Fossick Capital LP ("Fossick"), a limited partnership. The Reporting Person holds all voting and dispositive control over the Issuer's shares of common stock held by Fossick. Read SEC document |
| June 22, 2021 Filed Jun 24, 2021 21:54 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption (right to buy) · Derivative | 19,025 | $0.00 Strike: $17.49 | $0.00 |
DisclosureSEC source: 0001213900-21-034012 · ownership.xml · derivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,025 Underlying: Common Stock · 19,025 shares Expires 2031-06-21 F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc. F2 · derivative.exercise_date: Options granted pursuant to the Company's 2021 Stock Incentive Plan. These Options vest on a pro rata quarterly basis over three years such that all options to purchase the 19,025 shares will have vested on the third anniversary of the grant date. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 21:34 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption (right to buy) · Derivative | 15,975 | $0.00 Strike: $24.82 | $0.00 |
DisclosureSEC source: 0001213900-21-003484 · ownership.xml · derivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,975 Underlying: Common Stock · 15,975 shares Expires 2031-01-18 F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc. F3 · price: Not applicable F2 · derivative.exercise_date: Options granted pursuant to 2019 Stock Incentive Plan. Options shall vest on a pro rata quarterly basis over three years such that all options to purchase the 15,975 shares will have vested on the third anniversary of the grant date. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:36 UTC | Inmune Bio, Inc. INMB · Entity 7094 | GrantOption · Derivative | 108,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001213900-19-024954 · ownership.xml · derivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,000 Underlying: Common Stock · 108,000 shares Expires not disclosed F1 · shares: Each Option represents a right to receive one share of common stock of INmune Bio, Inc. F2 · derivative.exercise_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant. F2 · derivative.expiration_date: Vests pro rata on a monthly basis over three years (1/36) such that the Option will be fully vested three years from the date of grant. Read SEC document |
| August 21, 2019 Filed Aug 22, 2019 20:30 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 2,500 | $6.00 | $15,000.00 |
DisclosureSEC source: 0001213900-19-016514 · ownership.xml · nonDerivative · entry 2 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 F1 · shares: The Reporting Person purchased 2,500 shares of the Issuer's common stock in an open market transaction on August 20, 2019 and 2,5000 shares of the Issuer's common stock in an open market transaction on August 21, 2019. F2 · balance_after: The Reporting Person's shares are held by Fossick Capital LP ("Fossick"), a limited partnership. The Reporting Person holds all voting and dispositive control over the Issuer's shares of common stock held by Fossick. Read SEC document |
| August 20, 2019 Filed Aug 22, 2019 20:30 UTC | Inmune Bio, Inc. INMB · Entity 7094 | PurchaseCommon Stock | 2,500 | $6.00 | $15,000.00 |
DisclosureSEC source: 0001213900-19-016514 · ownership.xml · nonDerivative · entry 1 Juda Scott · CIK 0001767084 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: The Reporting Person purchased 2,500 shares of the Issuer's common stock in an open market transaction on August 20, 2019 and 2,5000 shares of the Issuer's common stock in an open market transaction on August 21, 2019. F2 · balance_after: The Reporting Person's shares are held by Fossick Capital LP ("Fossick"), a limited partnership. The Reporting Person holds all voting and dispositive control over the Issuer's shares of common stock held by Fossick. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.